A Review of Intravenous Minocycline for Treatment of Multidrug-Resistant Acinetobacter Infections
Clinical Infectious Diseases December 1, 2014 V.59 suppl 6 S374-S380
David J. Ritchie1,2 and Alexandria Garavaglia-Wilson2,3
1Department of Pharmacy, Barnes-Jewish Hospital
2Pharmacy Practice Department, St Louis College of Pharmacy
3Infectious Diseases Clinic, Washington University School of Medicine, St Louis, Missouri
Correspondence: David J. Ritchie, PharmD, FCCP, BCPS, Barnes-Jewish Hospital and St. Louis College of Pharmacy, Mailstop 90-52-411, 216 S Kingshighway Blvd, St Louis, MO 63110 (firstname.lastname@example.org).
Options for treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections are extremely limited.
Minocycline intravenous is active against many MDR strains of Acinetobacter, and Clinical and Laboratory Standards Institute breakpoints exist to guide interpretation of minocycline susceptibility results with Acinetobacter.
In addition, minocycline intravenous holds a US Food and Drug Administration indication for treatment of infections caused by Acinetobacter.
There is an accumulating amount of literature reporting successful use of minocycline intravenous for treatment of serious MDR Acinetobacter infections, particularly for nosocomial pneumonia.
These results, coupled with the generally favorable tolerability of minocycline intravenous, support its use as a viable therapeutic option for treatment of MDR Acinetobacter infections.